MedWatch

EMA agree to review Veloxis’ main asset

The European Medicines Authority (EMA) has begun reviewing the main asset from Danish company Veloxis, the candidate drug LCP-Tacro.

Foto: Colourbox

During 2014 Danish biotech company Veloxis will receive a crucial verdict, as the company can expect the final decision in a review that the EMA has just agreed to initiate.

Tuesday evening Veloxis announced that EMA has begun review of the company’s marketing authorization application (MAA) for LCP-Tacro for the prevention of organ rejection in kidney transplant patients in the European Union.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier